Forskning
Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital
Udgivet

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Hansen, CS, Frandsen, CS, Fleischer, J, Vistisen, D, Holst, JJ, Tarnow, L, Knop, FK, Madsbad, S, Andersen, HU & Dejgaard, TF 2019, 'Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes', Frontiers in Endocrinology, bind 10, 242. https://doi.org/10.3389/fendo.2019.00242

APA

Hansen, C. S., Frandsen, C. S., Fleischer, J., Vistisen, D., Holst, J. J., Tarnow, L., Knop, F. K., Madsbad, S., Andersen, H. U., & Dejgaard, T. F. (2019). Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. Frontiers in Endocrinology, 10, [242]. https://doi.org/10.3389/fendo.2019.00242

CBE

MLA

Vancouver

Author

Hansen, Christian Stevns ; Frandsen, Christian Seerup ; Fleischer, Jesper ; Vistisen, Dorte ; Holst, Jens Juul ; Tarnow, Lise ; Knop, Filip Krag ; Madsbad, Sten ; Andersen, Henrik Ullits ; Dejgaard, Thomas Fremming. / Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. I: Frontiers in Endocrinology. 2019 ; Bind 10.

Bibtex

@article{6bb86b7707d948d5ae3e05dc6cf48a1b,
title = "Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes",
abstract = "The role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown. We assessed the association between autonomic function and weight loss induced by the GLP-1 RA liraglutide. Methods: Lira-1 was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of 1.8 mg liraglutide once-daily for 24 weeks in overweight patients with type 1 diabetes. Autonomic function was assessed by heart rate response to deep breathing (E/I ratio), to standing (30/15 ratio), to the Valsalva maneuver and resting heart rate variability (HRV) indices. Associations between baseline the cardiovascular autonomic neuropathy (CAN) diagnosis (> 1 pathological non-resting test) and levels of test outcomes on liraglutide-induced weight loss was assessed by linear regression models. Results: Ninety-nine patients with mean age 48 (SD 12) years, HbA1c 70 (IQR 66;75) mmol/mol and BMI of 30 (SD 3) kg/m2 were assigned to liraglutide (N = 50) or placebo (N = 49). The CAN diagnosis was not associated with weight loss. A 50% higher baseline level of the 30/15 ratio was associated with a larger weight reduction by liraglutide of -2.65 kg during the trial (95% CI: -4.60; -0.69; P = 0.009). Similar significant associations were found for several HRV indices. Conclusions: The overall CAN diagnosis was not associated with liraglutide-induced weight loss in overweight patients with type 1 diabetes. Assessed separately, better outcomes for several CAN measures were associated with higher weight loss, indicating that autonomic involvement in liraglutide-induced weight loss may exist.",
keywords = "Autonomic neuropathy, Insulin requirements, Liraglutide, Type 1 diabetes, Weight loss",
author = "Hansen, {Christian Stevns} and Frandsen, {Christian Seerup} and Jesper Fleischer and Dorte Vistisen and Holst, {Jens Juul} and Lise Tarnow and Knop, {Filip Krag} and Sten Madsbad and Andersen, {Henrik Ullits} and Dejgaard, {Thomas Fremming}",
year = "2019",
month = apr,
day = "12",
doi = "10.3389/fendo.2019.00242",
language = "English",
volume = "10",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes

AU - Hansen, Christian Stevns

AU - Frandsen, Christian Seerup

AU - Fleischer, Jesper

AU - Vistisen, Dorte

AU - Holst, Jens Juul

AU - Tarnow, Lise

AU - Knop, Filip Krag

AU - Madsbad, Sten

AU - Andersen, Henrik Ullits

AU - Dejgaard, Thomas Fremming

PY - 2019/4/12

Y1 - 2019/4/12

N2 - The role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown. We assessed the association between autonomic function and weight loss induced by the GLP-1 RA liraglutide. Methods: Lira-1 was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of 1.8 mg liraglutide once-daily for 24 weeks in overweight patients with type 1 diabetes. Autonomic function was assessed by heart rate response to deep breathing (E/I ratio), to standing (30/15 ratio), to the Valsalva maneuver and resting heart rate variability (HRV) indices. Associations between baseline the cardiovascular autonomic neuropathy (CAN) diagnosis (> 1 pathological non-resting test) and levels of test outcomes on liraglutide-induced weight loss was assessed by linear regression models. Results: Ninety-nine patients with mean age 48 (SD 12) years, HbA1c 70 (IQR 66;75) mmol/mol and BMI of 30 (SD 3) kg/m2 were assigned to liraglutide (N = 50) or placebo (N = 49). The CAN diagnosis was not associated with weight loss. A 50% higher baseline level of the 30/15 ratio was associated with a larger weight reduction by liraglutide of -2.65 kg during the trial (95% CI: -4.60; -0.69; P = 0.009). Similar significant associations were found for several HRV indices. Conclusions: The overall CAN diagnosis was not associated with liraglutide-induced weight loss in overweight patients with type 1 diabetes. Assessed separately, better outcomes for several CAN measures were associated with higher weight loss, indicating that autonomic involvement in liraglutide-induced weight loss may exist.

AB - The role of the autonomic nervous system in the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in patients with type 1 diabetes is unknown. We assessed the association between autonomic function and weight loss induced by the GLP-1 RA liraglutide. Methods: Lira-1 was a randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of 1.8 mg liraglutide once-daily for 24 weeks in overweight patients with type 1 diabetes. Autonomic function was assessed by heart rate response to deep breathing (E/I ratio), to standing (30/15 ratio), to the Valsalva maneuver and resting heart rate variability (HRV) indices. Associations between baseline the cardiovascular autonomic neuropathy (CAN) diagnosis (> 1 pathological non-resting test) and levels of test outcomes on liraglutide-induced weight loss was assessed by linear regression models. Results: Ninety-nine patients with mean age 48 (SD 12) years, HbA1c 70 (IQR 66;75) mmol/mol and BMI of 30 (SD 3) kg/m2 were assigned to liraglutide (N = 50) or placebo (N = 49). The CAN diagnosis was not associated with weight loss. A 50% higher baseline level of the 30/15 ratio was associated with a larger weight reduction by liraglutide of -2.65 kg during the trial (95% CI: -4.60; -0.69; P = 0.009). Similar significant associations were found for several HRV indices. Conclusions: The overall CAN diagnosis was not associated with liraglutide-induced weight loss in overweight patients with type 1 diabetes. Assessed separately, better outcomes for several CAN measures were associated with higher weight loss, indicating that autonomic involvement in liraglutide-induced weight loss may exist.

KW - Autonomic neuropathy

KW - Insulin requirements

KW - Liraglutide

KW - Type 1 diabetes

KW - Weight loss

UR - http://www.scopus.com/inward/record.url?scp=85067649053&partnerID=8YFLogxK

U2 - 10.3389/fendo.2019.00242

DO - 10.3389/fendo.2019.00242

M3 - Journal article

C2 - 31031712

VL - 10

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

M1 - 242

ER -

ID: 57074528